List of works - Carsten Utoft Niemann

Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

scientific article published on 14 December 2020

Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study

scientific article published on 20 July 2020

B-cell receptor signaling as a driver of lymphoma development and evolution

scientific article

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

scientific article published on 29 June 2020

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

scientific article published on 01 November 2021

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

scientific article published on 09 July 2020

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

scientific article published on 31 August 2020

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

scientific article published on 23 May 2017

Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib

publication published on 07 May 2021

Cocreated Smartphone App to Improve the Quality of Life of Adolescents and Young Adults with Cancer (Kræftværket): Protocol for a Quantitative and Qualitative Evaluation.

scientific article published on 10 May 2018

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

scientific article published on 23 June 2017

Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

scientific article published on 24 September 2020

Correction: Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

scientific article published on 27 July 2020

Cost-effectiveness targeting CLL

scientific article published on 01 October 2020

Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

scientific article published on 04 December 2018

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study

scientific article published on 26 February 2018

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

scientific article published on 21 December 2020

Developing Age-Appropriate Supportive Facilities, Resources, and Activities for Adolescents and Young Adults with Cancer Across Departments and Diagnoses: A Single-Center Experience

scientific article published on 03 November 2018

Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study

scientific article published on 28 May 2020

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

scientific article published on 19 May 2016

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

scientific article

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

scientific article published on 9 December 2015

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

scientific article published on 01 September 2019

Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

scientific article published in 2022

Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

scientific article published on 13 December 2018

Expression analyses of human cleft palate tissue suggest a role for osteopontin and immune related factors in palatal development

scientific article published on February 2009

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

scientific article published on 29 September 2020

Highly glycosylated alpha1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils

scientific article published on 7 June 2005

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death

scientific article

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study

scientific article published on 03 October 2019

Ibrutinib and Venetoclax for First-Line Treatment of CLL

scientific article published on 01 August 2019

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

scientific article

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

scientific article published on 29 January 2018

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

scientific article

Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark.

scientific article published in July 2018

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

scientific article

Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study

scientific article published on 8 March 2018

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

scientific article

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

scientific article

Localization of serglycin in human neutrophil granulocytes and their precursors

scientific article

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

scientific article published on 17 January 2020

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

scientific article published on 27 December 2016

Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura

scientific article

Neutrophil elastase depends on serglycin proteoglycan for localization in granules

scientific article published on 01 February 2007

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

scientific article published on 21 December 2017

On mouse and man: neutrophil gelatinase associated lipocalin is not involved in apoptosis or acute response

scientific article

Pain characteristics and management of inpatients admitted to a comprehensive cancer centre: a cross-sectional study

scientific article published on 22 January 2013

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

scientific article published on 23 July 2020

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

scientific article published on 16 August 2022

Positive results with haematology webcasting for junior doctors ⬇️

scientific article published in January 2016

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR ⬇️

scientific article published on 15 October 2020

Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre.

scientific article

Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)

scientific article published on 8 August 2022

Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

scientific article published on 31 July 2020

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

scientific article

Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study

scientific article published on 07 February 2020

Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study

Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia

scientific article published on 11 October 2007

Serglycin proteoglycan is not implicated in localizing exocrine pancreas enzymes to zymogen granules.

scientific article published on 14 May 2009

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

scientific article

Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where

scientific article

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

scientific article published on 17 August 2017

Targeted treatment of chronic lymphocytic leukaemia ⬇️

scientific article published in April 2014

Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies

scientific article published on 01 November 2018

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

scientific article published on 30 November 2016

The CLL-IPI applied in a population-based cohort

scientific article published on 07 September 2016

The Danish National Chronic Lymphocytic Leukemia Registry

scientific article

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

scientific article published on 09 January 2020

Towards targeted therapy of chronic lymphocytic leukemia

scientific article published on January 2013

Using Cocreation in the Process of Designing a Smartphone App for Adolescents and Young Adults With Cancer: Prototype Development Study

scientific article published on 01 November 2018

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

scientific article published on 07 October 2020

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

scientific article published on 04 June 2019

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

scientific article published on 01 September 2020

Washington DC vs. Copenhagen

scientific article

List of works by Carsten Utoft Niemann

Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study

B-cell receptor signaling as a driver of lymphoma development and evolution

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib

Cocreated Smartphone App to Improve the Quality of Life of Adolescents and Young Adults with Cancer (Kræftværket): Protocol for a Quantitative and Qualitative Evaluation.

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

Correction: Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

Cost-effectiveness targeting CLL

Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Developing Age-Appropriate Supportive Facilities, Resources, and Activities for Adolescents and Young Adults with Cancer Across Departments and Diagnoses: A Single-Center Experience

Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

Expression analyses of human cleft palate tissue suggest a role for osteopontin and immune related factors in palatal development

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Highly glycosylated alpha1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark.

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Localization of serglycin in human neutrophil granulocytes and their precursors

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura

Neutrophil elastase depends on serglycin proteoglycan for localization in granules

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

On mouse and man: neutrophil gelatinase associated lipocalin is not involved in apoptosis or acute response

Pain characteristics and management of inpatients admitted to a comprehensive cancer centre: a cross-sectional study

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

Positive results with haematology webcasting for junior doctors ⬇️

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR ⬇️

Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre.

Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)

Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study

Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study

Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia

Serglycin proteoglycan is not implicated in localizing exocrine pancreas enzymes to zymogen granules.

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Targeted treatment of chronic lymphocytic leukaemia ⬇️

Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

The CLL-IPI applied in a population-based cohort

The Danish National Chronic Lymphocytic Leukemia Registry

The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

Towards targeted therapy of chronic lymphocytic leukemia

Using Cocreation in the Process of Designing a Smartphone App for Adolescents and Young Adults With Cancer: Prototype Development Study

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Washington DC vs. Copenhagen

[In Process Citation] ⬇️